126 related articles for article (PubMed ID: 18537966)
1. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
Moreau AS; Jia X; Patterson CJ; Roccaro AM; Xu L; Sacco A; O'Connor K; Soumerai J; Ngo HT; Hatjiharissi E; Hunter ZR; Ciccarelli B; Manning R; Ghobrial IM; Leleu X; Treon SP
Br J Haematol; 2008 Sep; 142(5):775-85. PubMed ID: 18537966
[TBL] [Abstract][Full Text] [Related]
2. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
Qi XF; Zheng L; Lee KJ; Kim DH; Kim CS; Cai DQ; Wu Z; Qin JW; Yu YH; Kim SK
Cell Death Dis; 2013 Feb; 4(2):e518. PubMed ID: 23449454
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Roccaro AM; Leleu X; Sacco A; Moreau AS; Hatjiharissi E; Jia X; Xu L; Ciccarelli B; Patterson CJ; Ngo HT; Russo D; Vacca A; Dammacco F; Anderson KC; Ghobrial IM; Treon SP
Clin Cancer Res; 2008 Mar; 14(6):1849-58. PubMed ID: 18347188
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
Sun JY; Tseng H; Xu L; Hunter Z; Ciccarelli B; Fulciniti M; Zhu B; Maghsoudi K; Yang G; Gong P; Zhou Y; Liu X; Munshi NC; Patterson CJ; Treon SP
Leuk Lymphoma; 2011 Sep; 52(9):1777-86. PubMed ID: 21657958
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase.
Koyuturk M; Ersoz M; Altiok N
Neurosci Lett; 2004 Nov; 370(2-3):212-7. PubMed ID: 15488325
[TBL] [Abstract][Full Text] [Related]
9. Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells.
Otsuki T; Sakaguchi H; Hatayama T; Fujii T; Tsujioka T; Sugihara T; Takata A; Hyodoh F; Eto M
Oncol Rep; 2004 May; 11(5):1053-8. PubMed ID: 15069546
[TBL] [Abstract][Full Text] [Related]
10. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
[TBL] [Abstract][Full Text] [Related]
11. Statin post-treatment provides protection against simulated ischemia in bovine pulmonary arterial endothelial cells.
Wu X; Lin D; Li G; Zuo Z
Eur J Pharmacol; 2010 Jun; 636(1-3):114-20. PubMed ID: 20361961
[TBL] [Abstract][Full Text] [Related]
12. The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
Stine JE; Guo H; Sheng X; Han X; Schointuch MN; Gilliam TP; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Jan; 7(1):946-60. PubMed ID: 26503475
[TBL] [Abstract][Full Text] [Related]
13. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
Leleu X; Jia X; Runnels J; Ngo HT; Moreau AS; Farag M; Spencer JA; Pitsillides CM; Hatjiharissi E; Roccaro A; O'Sullivan G; McMillin DW; Moreno D; Kiziltepe T; Carrasco R; Treon SP; Hideshima T; Anderson KC; Lin CP; Ghobrial IM
Blood; 2007 Dec; 110(13):4417-26. PubMed ID: 17761832
[TBL] [Abstract][Full Text] [Related]
14. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA.
Choi M; Rolle S; Rane M; Haller H; Luft FC; Kettritz R
Kidney Int; 2003 Jan; 63(1):96-106. PubMed ID: 12472772
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H
Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376
[TBL] [Abstract][Full Text] [Related]
16. Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells.
Pelaia G; Gallelli L; Renda T; Fratto D; Falcone D; Caraglia M; Busceti MT; Terracciano R; Vatrella A; Maselli R; Savino R
Cell Prolif; 2012 Dec; 45(6):557-65. PubMed ID: 23045963
[TBL] [Abstract][Full Text] [Related]
17. Involvement of ERK and AKT signaling in the growth effect of arginine vasopressin on adult rat cardiac fibroblast and the modulation by simvastatin.
He YP; Zhao LY; Zheng QS; Liu SW; Zhao XY; Lu XL; Niu XL; Li X
Mol Cell Biochem; 2008 Oct; 317(1-2):33-41. PubMed ID: 18581203
[TBL] [Abstract][Full Text] [Related]
18. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.
Blanco-Colio LM; Villa A; Ortego M; Hernández-Presa MA; Pascual A; Plaza JJ; Egido J
Atherosclerosis; 2002 Mar; 161(1):17-26. PubMed ID: 11882313
[TBL] [Abstract][Full Text] [Related]
19. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
Biochem Biophys Res Commun; 2008 Sep; 374(2):309-14. PubMed ID: 18625202
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway.
Yamashita M; Otsuka F; Mukai T; Otani H; Inagaki K; Miyoshi T; Goto J; Yamamura M; Makino H
J Endocrinol; 2008 Mar; 196(3):601-13. PubMed ID: 18310456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
